Clinical score for early escalation in pediatric A2063G Mycoplasma pneumoniae pneumonia: a retrospective cohort study.

ABSTRACT:

Background

Macrolide-resistant Mycoplasma pneumoniae (MRMP), primarily driven by the 23 S rRNA A2063G mutation, is increasingly prevalent among East Asian children, diminishing azithromycin efficacy. Although some patients benefit from its anti-inflammatory properties, delayed escalation in non-responders can prolong fever and increase complications. Given the age-related risks of tetracyclines and fluoroquinolones, determining which children truly require second-line therapy remains a clinical challenge.

Methods

We retrospectively reviewed 112 children with MRMP carrying the 23 S rRNA A2063G mutation. Patients were categorized into an azithromycin group (n = 66) and a second-line therapy group (n = 46). Between-group comparisons were performed using the χ² test, independent

SUBMITTER: Ning J 

PROVIDER: S-EPMC12481833 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature